Lv5
1010 积分 2025-02-27 加入
Current situation of zalutumumab
1个月前
已完结
ERBB receptors and cancer: the complexity of targeted inhibitors
5个月前
已完结
Emerging importance of HER3 in tumorigenesis and cancer therapy
5个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
6个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
6个月前
已完结
Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study
6个月前
已完结
Major Strides in HER2 Blockade for Metastatic Breast Cancer
7个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
7个月前
已完结
Thirty Years of HER3: From Basic Biology to Therapeutic Interventions
7个月前
已完结
皖公网安备34019202002308
